New Zacks report out today.

"We expect clinical trials to begin in 2021 for both candidates."  Referring to XB3-001 and XB3-007

Seems like an ambitious statement, but I suspect there is a lot more going on behind the scenes than most retail investors are privy to.  Could be an interesting second half of 2021, seems like we finally have a few irons in the fire, or shots on goal, or chose your metaphor.

Happy Canada Day to my friends up north, and Happy Fourth to those of us down in the States.